Wegovy 2.0 mg: making sense of your second dose step

You searched for 2.0 mg, here's where that sits in the real Wegovy programme

The confusion is understandable. Dose numbers circulate on forums, in packaging photos, and across social media, and "2.0" looks plausible next to doses like 1.7 and 2.4. But Wegovy's licensed titration schedule, as set out in the Summary of Product Characteristics published on the electronic Medicines Compendium, has no 2.0 mg step.

The sequence your prescriber follows is: 0.25 mg for the first four weeks (a tolerability phase, the first pen's job is to let your system adjust, not to drive weight loss), then 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg as the standard maintenance dose. Each step is typically four weeks apart. A prescriber may slow the titration if side effects are significant, that's clinical judgement, not the schedule changing.

If you read something labelled "2.0 mg" in the context of semaglutide weight-loss treatment, it may be a misremembered dose, a reference to a different medicine entirely, or content from a country with a different licensing arrangement. The UK schedule is the one that matters here, and it goes 0.25, 0.5, 1.0, 1.7, 2.4. You can read more about the full programme on our Wegovy overview page.

The 2.4 mg dose was studied extensively in the STEP 1 trial (68 weeks, over 1,900 adults with obesity or overweight and a weight-related condition) where participants taking semaglutide 2.4 mg alongside lifestyle changes achieved an average body-weight reduction of around 15%, compared with about 2.4% in the placebo group. Those figures come from the STEP 1 trial, published in the New England Journal of Medicine.

The 7.2 mg update: where Wegovy's dose ceiling now sits

Since early 2026 the picture has changed. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, a pre-set weekly injection with an auto-dosing mechanism, a covered needle that locks after use, and no need to dial a dose. This followed the January 2026 approval of 7.2 mg as a maintenance option (initially delivered as multiple 2.4 mg pens per week), and you can find full details about that earlier formulation on our Wegovy 2 page.

The 7.2 mg pen is licensed for adults with a BMI of 30 or above, not for the lower BMI threshold or the cardiovascular indication. The titration still starts at 0.25 mg; reaching 7.2 mg means working through all the earlier steps under prescriber supervision. Trial data at this higher dose showed average weight loss of around 20.7% over 72 weeks, which closes much of the gap between Wegovy and tirzepatide results in earlier studies.

What this means practically is that the ceiling for semaglutide-based weight management is now higher than it was a year ago. Whether 7.2 mg is appropriate for a specific patient is a clinical decision. If you want to understand which treatment might suit your situation, our semaglutide 2.0 page covers what that label refers to and how it fits into the broader landscape of semaglutide options. Details on the MHRA's April 2026 approval are published on GOV.UK under the announcement for the single-dose 7.2 mg semaglutide pen.

Side effects as your dose increases, what tends to shift at each step

Most of the side effects people notice on Wegovy are gastrointestinal. Nausea, an unsettled stomach, looser stools, and occasional vomiting are the most common, and they tend to be at their most noticeable in the first week or two after each dose increase. The 0.25 mg starting dose exists precisely to let your body adjust before the medicine is doing its main job, which is why skipping straight to a higher step is not how the programme works.

By the time patients reach 1.7 mg or 2.4 mg, many find the GI effects have settled considerably, though this varies. Other side effects recorded in trials include headache, fatigue, and injection-site reactions. The NHS medicines information for semaglutide lists the full profile; the NHS semaglutide page is the clearest starting point for most readers.

One signal to take seriously at any dose: severe, persistent abdominal pain that radiates to the back. This can be a sign of pancreatitis, which the MHRA highlighted in a January 2026 Drug Safety Update on GLP-1 medicines. It's uncommon, but it warrants urgent medical attention. Report any suspected side effects at the MHRA's Yellow Card scheme, patients can do this directly, not just clinicians.

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for anyone under 18. Medical history, current medicines, and any relevant conditions all feed into the prescriber's assessment before treatment starts or a dose changes.

Getting the dose right: why this is a clinical conversation, not a self-selection

A question our prescribers hear regularly is whether someone can request a specific dose, skip 1.7 mg and go straight to 2.4 mg, say, because they feel ready. The honest answer is that the titration schedule isn't arbitrary. Each four-week step gives your body time to adapt, which is why the MHRA-approved programme is structured the way it is.

For people considering where to get Wegovy through a private route, the process at a regulated online pharmacy involves a clinical consultation and review of your full health picture before treatment begins and before each dose change, and our Wegovy 1.0 page explains what to expect at that earlier stage of the titration. That review isn't a formality, it's the mechanism that keeps the programme safe.

The weight-loss treatments overview explains what's available in the UK and the difference between NHS and private routes. If you'd like to explore whether Wegovy or another licensed treatment is right for you, the next step is a clinical consultation, and our 2.7 mg Wegovy page covers that part of the titration in more detail for anyone who wants to understand each step before starting. At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber. Start your free consultation at our treatment page.